Rituximab for the treatment of Churg-Strauss syndrome with renal involvement

Nephrology Dialysis Transplantation

Volumn 26, Issue 9, 2011, Pages 2865-2871

  Cartin Ceba, Rodrigo ^a   Keogh, Karina A ^a   Specks, Ulrich ^a   Sethi, Sanjeev ^a   Fervenza, Fernando C ^a  

^a MAYO CLINIC   (United States)

Author keywords

ANCA vasculitis; Churg Strauss syndrome; glomerulonephritis; rituximab

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CD19 ANTIGEN; CREATININE; CYCLOPHOSPHAMIDE; GLUCOCORTICOID; LONG ACTING DRUG; MEPREDNISONE; METHOTREXATE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISONE; RITUXIMAB; STEROID;

ADULT; AGED; ARTICLE; ASTHMA; CASE REPORT; CHURG STRAUSS SYNDROME; CLINICAL TRIAL; CREATININE CLEARANCE; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; EOSINOPHILIA; ERYTHROCYTE DISORDER; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY DISEASE; MALE; OPEN STUDY; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; REMISSION; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CHURG-STRAUSS SYNDROME; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOLOGIC FACTORS; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PILOT PROJECTS; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 80053215159     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq852     Document Type: Article

References (37)

1. Churg J, Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am J Pathol 1951; 27: 277-301
2. Abril A, Calamia KT, Cohen MD. The Churg Strauss syndrome (allergic granulomatous angiitis): review and update. Semin Arthritis Rheum 2003; 33: 106-114 (Pubitemid 37386204)
3. Eustace JA, Nadasdy T, Choi M. Disease of the month. The Churg Strauss syndrome. J Am Soc Nephrol 1999; 10: 2048-2055 (Pubitemid 29402528)
4. Gross WL. Churg-Strauss syndrome: update on recent developments. Curr Opin Rheumatol 2002; 14: 11-14 (Pubitemid 34059883)
5. Keogh KA, Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am J Med 2003; 115: 284-290 (Pubitemid 37088190)
6. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet 2003; 361: 587-594 (Pubitemid 36207480)
7. Keogh KA, Specks U. Churg-Strauss syndrome. Semin Respir Crit Care Med 2006; 27: 148-157
8. Clutterbuck EJ, Evans DJ, Pusey CD. Renal involvement in Churg-Strauss syndrome. Nephrol Dial Transplant 1990; 5: 161-167 (Pubitemid 20172141)
9. Kikuchi Y, Ikehata N, Tajima O et al. Glomerular lesions in patients with Churg-Strauss syndrome and the anti-myeloperoxidase antibody. Clin Nephrol 2001; 55: 429-435 (Pubitemid 32499496)
10. Gayraud M, Guillevin L, Le Toumelin P et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001; 44: 666-675 (Pubitemid 32234626)
11. Bosch X, Guilabert A, Espinosa G et al. Treatment of antineutrophil cytoplasmic antibody associated vasculitis: a systematic review. JAMA 2007; 298: 655-669 (Pubitemid 47236417)
12. Stone JH, Merkel PA, Spiera R et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med 2010; 363: 221-232
13. Jones RB, Tervaert JW, Hauser T et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 2010; 363: 211-220
14. Keogh KA, Ytterberg SR, Fervenza FC et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006; 173: 180-187 (Pubitemid 43187890)
15. Keogh KA, Wylam ME, Stone JH et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005; 52: 262-268 (Pubitemid 40129256)
16. Donvik KK, Omdal R. Churg-Strauss syndrome successfully treated with rituximab. Rheumatol Int 2009; 31: 89-91
17. Kaushik VV, Reddy HV, Bucknall RC. Successful use of rituximab in a patient with recalcitrant Churg-Strauss syndrome. Ann Rheum Dis 2006; 65: 1116-1117 (Pubitemid 44133281)
18. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006; 65: 557-559
19. Pepper RJ, Fabre MA, Pavesio C et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008; 47: 1104-1105 (Pubitemid 351865947)
20. Saech J, Owczarzyk K, Rosgen S et al. Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement. Ann Rheum Dis 2010; 69: 1254-1255
21. Lanham JG, Elkon KB, Pusey CD et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63: 65-81 (Pubitemid 14166819)
22. Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990; 33: 1094-1100 (Pubitemid 20273293)
23. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994; 37: 187-192 (Pubitemid 24065492)
24. Merkel PA, Cuthbertson DD, Hellmich B et al. Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. Ann Rheum Dis 2009; 68: 103-106
25. Stone JH, Hoffman GS, Merkel PA et al. A disease-specific activity index for Wegener's granulomatosis: modification of the Birmingham Vasculitis Activity Score. International Network for the Study of the Systemic Vasculitides (INSSYS). Arthritis Rheum 2001; 44: 912-920 (Pubitemid 32319784)
26. Isenberg DA. B cell targeted therapies in autoimmune diseases. J Rheumatol Suppl 2006; 77: 24-28
27. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibodypositive vasculitis successfully treated with rituximab. J Intern Med 2005; 257: 540-548 (Pubitemid 40776514)
28. Brihaye B, Aouba A, Pagnoux C et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin Exp Rheumatol 2007; 25: S23-S27 (Pubitemid 46656590)
29. Smith KG, Jones RB, Burns SM et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982 (Pubitemid 44497778)
30. Bouldouyre MA, Cohen P, Guillevin L. Severe bronchospasm associated with rituximab for refractory Churg-Strauss syndrome. Ann Rheum Dis 2009; 68: 606
31. Sneller MC. Rituximab and Wegener's granulomatosis: are B cells a target in vasculitis treatment? Arthritis Rheum 2005; 52: 1-5 (Pubitemid 40129225)
32. Omdal R,Wildhagen K, Hansen T et al. Anti-CD20 therapy of treatmentresistant Wegener's granulomatosis: favourable but temporary response. Scand J Rheumatol 2005; 34: 229-232 (Pubitemid 40978644)
33. Ferraro AJ, Day CJ, Drayson MT et al. Effective therapeutic use of rituximab in refractory Wegener's granulomatosis. Nephrol Dial Transplant 2005; 20: 622-625 (Pubitemid 40378435)
34. Cambridge G, Leandro MJ, Edwards JC et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003; 48: 2146-2154 (Pubitemid 36959194)
35. De Vita S, Zaja F, Sacco S et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002; 46: 2029-2033
36. Jones RB, Ferraro AJ, Chaudhry AN et al. A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009; 60: 2156-2168
37. Manz RA, Hauser AE, Hiepe F et al. Maintenance of serum antibody levels. Annu Rev Immunol 2005; 23: 367-386 (Pubitemid 40563174)